Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer
Business Wire•18/11/2026•09:01 ET
1
Key Highlights
- ➤VS-7375 lung-cancer data selected for late-breaking oral presentation December 5, 2026
- ➤TARGET-D 202 Phase 2 NSCLC trial accepted for poster presentation
- ➤Verastem advances VS-7375 toward frontline treatment after confirmed responses in previously treated NSCLC
- ➤FDA granted Fast Track Designation for VS-7375 in KRAS G12D-mutated NSCLC
- ➤Verastem licensed VS-7375 development and commercialization rights outside GenFleet’s Greater China markets
Expert Statements
Michael G. Kauffman, M.D., Ph.D., President of Development at Verastem Oncology
“For people with KRAS G12D-mutated lung cancer, the need for targeted treatment options remains significant. No therapy specifically targeting KRAS G12D is approved, and published research has associated this mutation with worse outcomes, including lower response rates and shorter progression-free survival than other common KRAS variants in metastatic NSCLC.”
Michael G. Kauffman, M.D., Ph.D., President of Development at Verastem Oncology
“We’re advancing VS-7375, an investigational oral, selective KRAS G12D (ON/OFF) inhibitor with best-in-class potential to enable maximal antitumor efficacy with a favorable tolerability profile. The updated TARGET-D 101 data to be presented at the conference build on the findings we reported in October -- including confirmed responses in previously treated NSCLC, with responses observed in patients who had received taxanes. Together, these findings support our broader strategy to move VS-7375 toward the frontline setting.”
Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer
Updated Phase 1/2 TARGET-D 101 data for KRAS G12D-mutated metastatic NSCLC to be presented on December 5, 2026, during Oral Abstract Session 1
Get started
Create a free account to read the full story.
